Pharsight

Drugs that contain Rufinamide

1. Banzel patents expiration

BANZEL IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8076362 EISAI INC Crystal modification A of 1-(2,6-difluorobenzyI)-1 H-1,2,3-triazole-4-carboxamide and dosage forms and formulations thereof
Jun, 2018

(5 years ago)

US7750028 EISAI INC Crystal modifications of 1-(2,6-difluorobenzyl)-1H-1, 2,3-triazole-4-carboxamide
Oct, 2018

(5 years ago)

US8076362

(Pediatric)

EISAI INC Crystal modification A of 1-(2,6-difluorobenzyI)-1 H-1,2,3-triazole-4-carboxamide and dosage forms and formulations thereof
Dec, 2018

(5 years ago)

US7750028

(Pediatric)

EISAI INC Crystal modifications of 1-(2,6-difluorobenzyl)-1H-1, 2,3-triazole-4-carboxamide
Apr, 2019

(5 years ago)

US6740669 EISAI INC Crystal modification of 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide and its use as antiepileptic
Nov, 2022

(1 year, 6 months ago)

US6740669

(Pediatric)

EISAI INC Crystal modification of 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide and its use as antiepileptic
May, 2023

(1 year, 17 days ago)

Drug Exclusivity Drug Exclusivity Expiration
Pediatric Exclusivity(PED) May 14, 2016
New Chemical Entity Exclusivity(NCE) Nov 14, 2013
Orphan Drug Exclusivity(ODE) Nov 14, 2015

NCE-1 date: 15 May, 2015

Market Authorisation Date: 14 November, 2008

Treatment: Treatment of epilepsy

Dosage: TABLET;ORAL; SUSPENSION;ORAL

How can I launch a generic of BANZEL before it's drug patent expiration?
More Information on Dosage

BANZEL family patents

Family Patents